• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

    10/28/22 4:05:12 PM ET
    $TCDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCDA alert in real time by email
    SC 13G/A 1 tm2229124d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)*

     

    Tricida, Inc.

    (Name of Issuer)

     

    Common Stock, $0.001 par value

    (Title of Class of Securities)

     

    89610F101

    (CUSIP Number)

     

    October 25, 2022

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 89610F101 Page 2 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners II, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,982,5282

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     
                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 3 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,982,5282

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     
                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 4 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners III, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    2,982,5282

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 5 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Co-Investment Holdings III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    2,982,5282

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 6 of 17

     

               
    1.  

    Name of reporting persons

     

    Venrock Healthcare Capital Partners EG, L.P.

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    2,982,5282

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    PN

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 7 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management II, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    2,982,5282

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 8 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management III, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    2,982,5282

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 9 of 17

     

               
    1.  

    Name of reporting persons

     

    VHCP Management EG, LLC

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.  

    Sole Voting Power

     

    0

    6.  

    Shared Voting Power

     

    2,982,5282

    7.  

    Sole Dispositive Power

     

    0

    8.  

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    OO

                     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 10 of 17

     

             
    1.  

    Name of Reporting Persons

     

    Shah, Nimish

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,982,5282

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 11 of 17

     

             
    1.  

    Name of Reporting Persons

     

    Koh, Bong

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) x1 (b) ¨

     

    3.  

    SEC USE ONLY

     

    4.  

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,982,5282

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,982,5282

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,982,5282

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.  

    Percent of Class Represented by Amount in Row (9)

     

    5.4%3

    12.  

    Type of Reporting Person (See Instructions)

     

    IN

     

    1  Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management II, LLC, VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

     

    2  Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P.

     

    3  This percentage is calculated based upon 55,668,880 shares outstanding as of August 4, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2022.

     

     

     

     

    CUSIP No. 89610F101 Page 12 of 17

     

    Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners II, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP II LP”), VHCP Co-Investment Holdings II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment II”), Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management II, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management II”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP II LP, VHCP Co-Investment II, VHCP III LP, VHCP Co-Investment III, VHCP EG, VHCP Management II and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh”) in respect of Common Stock of Tricida, Inc.

     

    Item 1.

     

      (a) Name of Issuer

     

    Tricida, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    7000 Shoreline Court, Suite 201

    South San Francisco, CA 94080

     

    Item 2.

     

      (a) Name of Person Filing

     

    Venrock Healthcare Capital Partners II, L.P.

    VHCP Co-Investment Holdings II, LLC

    Venrock Healthcare Capital Partners III, L.P.

    VHCP Co-Investment Holdings III, LLC

    Venrock Healthcare Capital Partners EG, L.P.

    VHCP Management II, LLC

    VHCP Management III, LLC

    VHCP Management EG, LLC

    Nimish Shah

    Bong Koh

     

      (b) Address of Principal Business Office or, if none, Residence

     

      New York Office: Palo Alto Office:
         
      7 Bryant Park 3340 Hillview Avenue
      23rd Floor Palo Alto, CA 94304
      New York, NY 10018  

     

      (c) Citizenship

     

    All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

     

      (d) Title of Class of Securities

     

    Common Stock, par value $0.001 per share

     

      (e) CUSIP Number

     

    89610F101

     

     

     

     

    CUSIP No. 89610F101 Page 13 of 17

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

    Item 4. Ownership

     

      (a) Amount Beneficially Owned as of October 28, 2022:

     

    Venrock Healthcare Capital Partners II, L.P.   2,982,528(1)
    VHCP Co-Investment Holdings II, LLC   2,982,528(1)
    Venrock Healthcare Capital Partners III, L.P.   2,982,528(1)
    VHCP Co-Investment Holdings III, LLC   2,982,528(1)
    Venrock Healthcare Capital Partners EG, L.P.   2,982,528(1)
    VHCP Management II, LLC   2,982,528(1)
    VHCP Management III, LLC   2,982,528(1)
    VHCP Management EG, LLC   2,982,528(1)
    Nimish Shah   2,982,528(1)
    Bong Koh   2,982,528(1)

     

      (b) Percent of Class as of October 28, 2022:

     

    Venrock Healthcare Capital Partners II, L.P.   5.4%
    VHCP Co-Investment Holdings II, LLC   5.4%
    Venrock Healthcare Capital Partners III, L.P.   5.4%
    VHCP Co-Investment Holdings III, LLC   5.4%
    Venrock Healthcare Capital Partners EG, L.P.   5.4%
    VHCP Management II, LLC   5.4%
    VHCP Management III, LLC   5.4%
    VHCP Management EG, LLC   5.4%
    Nimish Shah   5.4%
    Bong Koh   5.4%

     

      (c) Number of shares as to which the person has, as of October 28, 2022:

     

      (i) Sole power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   0 
    VHCP Co-Investment Holdings II, LLC   0 
    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management II, LLC   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

     

     

     

    CUSIP No. 89610F101 Page 14 of 17

     

      (ii) Shared power to vote or to direct the vote

     

    Venrock Healthcare Capital Partners II, L.P.   2,982,528(1)
    VHCP Co-Investment Holdings II, LLC   2,982,528(1)
    Venrock Healthcare Capital Partners III, L.P.   2,982,528(1)
    VHCP Co-Investment Holdings III, LLC   2,982,528(1)
    Venrock Healthcare Capital Partners EG, L.P.   2,982,528(1)
    VHCP Management II, LLC   2,982,528(1)
    VHCP Management III, LLC   2,982,528(1)
    VHCP Management EG, LLC   2,982,528(1)
    Nimish Shah   2,982,528(1)
    Bong Koh   2,982,528(1)

     

      (iii) Sole power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   0 
    VHCP Co-Investment Holdings II, LLC   0 
    Venrock Healthcare Capital Partners III, L.P.   0 
    VHCP Co-Investment Holdings III, LLC   0 
    Venrock Healthcare Capital Partners EG, L.P.   0 
    VHCP Management II, LLC   0 
    VHCP Management III, LLC   0 
    VHCP Management EG, LLC   0 
    Nimish Shah   0 
    Bong Koh   0 

     

      (iv) Shared power to dispose or to direct the disposition of

     

    Venrock Healthcare Capital Partners II, L.P.   2,982,528(1)
    VHCP Co-Investment Holdings II, LLC   2,982,528(1)
    Venrock Healthcare Capital Partners III, L.P.   2,982,528(1)
    VHCP Co-Investment Holdings III, LLC   2,982,528(1)
    Venrock Healthcare Capital Partners EG, L.P.   2,982,528(1)
    VHCP Management II, LLC   2,982,528(1)
    VHCP Management III, LLC   2,982,528(1)
    VHCP Management EG, LLC   2,982,528(1)
    Nimish Shah   2,982,528(1)
    Bong Koh   2,982,528(1)

     

    (1) Consists of (i) 285,997 shares held by Venrock Healthcare Capital Partners II, L.P., (ii) 115,901 shares held by VHCP Co-Investment Holdings II, LLC, (iii) 871,850 shares held by Venrock Healthcare Capital Partners III, L.P., (iv) 87,200 shares held by VHCP Co-Investment Holdings III, LLC and (v) 1,621,580 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management II, LLC is the general partner of Venrock Healthcare Capital Partners II, L.P. and the manager of VHCP Co-Investment Holdings II, LLC. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management II, LLC, VHCP Management III, LLC and VHCP Management EG, LLC.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable

     

     

     

     

    CUSIP No. 89610F101 Page 15 of 17

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9. Notice of Dissolution of a Group

     

    Not Applicable

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 89610F101 Page 16 of 17

     


    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 28, 2022

     

    Venrock Healthcare Capital Partners II, L.P.   Venrock Healthcare Capital Partners III, L.P.
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: General Partner   Its: General Partner
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Co-Investment Holdings II, LLC   VHCP Co-Investment Holdings III, LLC
             
    By: VHCP Management II, LLC   By: VHCP Management III, LLC
    Its: Manager   Its: Manager
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    VHCP Management II, LLC   VHCP Management III, LLC
             
    By: /s/ David L. Stepp   By: /s/ David L. Stepp
      Name: David L. Stepp     Name: David L. Stepp
      Its: Authorized Signatory     Its: Authorized Signatory
         
    Venrock Healthcare Capital Partners EG, L.P.   VHCP Management EG, LLC
         
    By: VHCP Management EG, LLC   /s/ David L. Stepp
    Its: General Partner   Name: David L. Stepp
        Its: Authorized Signatory
    /s/ David L. Stepp    
    Name: David L. Stepp    
    Its: Authorized Signatory    

     

    Bong Koh  
       
    /s/ David L. Stepp  
    David L. Stepp, Attorney-in-fact  
       
    Nimish Shah  
       
    /s/ David L. Stepp  

    David L. Stepp, Attorney-in-fact

     

     

     

     

    CUSIP No. 89610F101 Page 17 of 17

     

    EXHIBITS

     

    A: Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed February 14, 2022)

     

    B: Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed February 14, 2022)

     

    C: Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed February 14, 2022)

     

     

     

    Get the next $TCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCDA

    DatePrice TargetRatingAnalyst
    4/13/2022$25.00Buy
    Goldman
    11/16/2021$7.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $TCDA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Tricida Inc.

      EFFECT - Tricida, Inc. (0001595585) (Filer)

      6/20/23 12:15:13 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 15-12G filed by Tricida Inc.

      15-12G - Tricida, Inc. (0001595585) (Filer)

      6/13/23 6:55:49 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Tricida Inc.

      S-8 POS - Tricida, Inc. (0001595585) (Filer)

      6/13/23 6:53:19 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Tricida with a new price target

      Goldman initiated coverage of Tricida with a rating of Buy and set a new price target of $25.00

      4/13/22 7:21:51 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida upgraded by JP Morgan with a new price target

      JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00

      11/16/21 5:20:40 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO

      Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology. This press release features multimedia. View the full release here: https://www.businesswire.c

      2/9/22 4:38:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 4:16:07 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 12:19:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

      SC 13G/A - Tricida, Inc. (0001595585) (Subject)

      2/14/23 8:58:08 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tricida Announces Third Quarter 2022 Financial Results

      Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in October the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration

      11/14/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Provides Strategic Update

      Tricida, Inc. (NASDAQ:TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor. This strategic review may include consideration of the sale of the Company and/or its assets. Tricida is also currently evaluating plans to reduce operating expenses and anticipates initiating and announcing these plans in November 2022. The Board of Directors and Tricida intend to conduct a thorough review of

      11/2/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

      Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla

      10/24/22 7:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Financials

    Live finance-specific insights

    See more
    • Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

      Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla

      10/24/22 7:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida Announces Second Quarter 2022 Financial Results

      Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that it stopped its VALOR-CKD renal outcomes trial early for administrative reasons as permitted by the existing study protocol to allow for six months of financial runway following the reporting of top-line results, which is anticipated to occur in October 2022. The VALOR-CKD trial has continued to accrue primary endpoint events as clinical trial subjects complete their participation in the study which, for the last subject, is currently projected to

      8/8/22 4:05:00 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022

      SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Second Quarter Financial Results Conference CallMonday, August 8, 20224:30 pm Eastern Time  Webcast:IR.Tricida.com Dial-in:(800) 715-9871 International:(646) 307-1963 Conference ID:3576787 A replay of the webcast will be available on Tricida's website approximately two hours

      8/1/22 10:00:00 AM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TCDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Orbimed Advisors Llc sold $2,205,635 worth of shares (10,280,947 units at $0.21)

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 8:13:12 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Bonita David P sold $2,205,635 worth of shares (10,280,947 units at $0.21)

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 8:08:35 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Alpern Robert J sold $27,695 worth of shares (131,879 units at $0.21), closing all direct ownership in the company

      4 - Tricida, Inc. (0001595585) (Issuer)

      11/25/22 4:13:54 PM ET
      $TCDA
      Biotechnology: Pharmaceutical Preparations
      Health Care